# SAFETY DATA SHEET



TEKNODUR COMBI 3560-15 - All variants

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : FEKNODUR COMBI 3560-15 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Paint.

1.3 Details of the supplier of the safety data sheet

Peknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : responsible for this SDS

: Prod-safe@teknos.com

National contact

₹eknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

**National advisory body/Poison Centre** 

Telephone number : In an emergency, call 112

## **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Fram. Liq. 3, H226 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms







Signal word : Danger

Hazard statements : H226 - Flammable liquid and vapour.

H314 - Causes severe skin burns and eye damage.

H317 - May cause an allergic skin reaction.

H412 - Harmful to aquatic life with long lasting effects.

**Precautionary statements** 

**Prevention**: \(\overline{\mathbb{P}}280\) - Wear protective gloves, protective clothing and eye or face protection.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

Label No : #0906

sources. No smoking.

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 1/18

# **SECTION 2: Hazards identification**

Response

: P304 + P310 - IF INHALED: Immediately call a POISON CENTER or doctor.

P301 + P310 - IF SWALLOWED: Immediately call a POISON CENTER or doctor. P303 + P361 + P353 - IF ON SKIN (or hair): Take off immediately all contaminated

clothing. Rinse skin with water.

**Storage** 

: Not applicable.

**Disposal** 

: P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

**Hazardous ingredients** 

: tetraethylN,N'-(methylenedicyclohexane-4,1-diyl)bis-dl-aspartate

1,3,3-trimethyl-N-(2-methylpropylidene)-5-[(2-methylpropylidene)amino]-

cyclohexanemethylamine

bis(4-(1,2-bis(ethoxycarbonyl)ethylamino)-3-methylcyclohexyl)methane Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl

1,2,2,6,6-pentamethyl-4-piperidyl sebacate

Supplemental label

elements

Marning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a

Other hazards which do not result in classification

: None known.

# **SECTION 3: Composition/information on ingredients**

3.2 Mixtures : Mixture

| Product/ingredient name   | Identifiers  | %         | Classification   | Specific Conc.<br>Limits, M-factors<br>and ATEs | Туре    |
|---|--|-----------|--|---|---------|
| retraethylN,N'-<br>(methylenedicyclohexane-<br>4,1-diyl)bis-dl-aspartate                                      | REACH #:<br>01-0000017556-64<br>EC: 429-270-1<br>CAS: 136210-30-5<br>Index: 607-521-00-8 | ≥10 - ≤25 | Skin Sens. 1, H317<br>Aquatic Chronic 3,<br>H412               | -   | [1]     |
| 1,3,3-trimethyl-N-<br>(2-methylpropylidene)-5-[<br>(2-methylpropylidene)<br>amino]-<br>cyclohexanemethylamine | REACH #:<br>01-2119978283-28<br>EC: 259-393-4<br>CAS: 54914-37-3                         | ≤10       | Skin Corr. 1C, H314<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317 | -   | [1]     |
| n-Butyl acetate   | REACH #:<br>01-2119485493-29<br>EC: 204-658-1<br>CAS: 123-86-4<br>Index: 607-025-00-1    | ≤10       | Flam. Liq. 3, H226<br>STOT SE 3, H336<br>EUH066                | -   | [1] [2] |
| bis(4-(1,2-bis<br>(ethoxycarbonyl)ethylamino)<br>-3-methylcyclohexyl)<br>methane                              | REACH #:<br>01-0000015937-58<br>EC: 412-060-9<br>CAS: 136210-32-7<br>Index: 607-350-00-9 | ≤10       | Skin Sens. 1, H317<br>Aquatic Chronic 3,<br>H412               | -   | [1]     |
| Xylene  | REACH #:<br>01-2119488216-32   | ≤5        | Flam. Liq. 3, H226<br>Acute Tox. 4, H312                       | ATE [Dermal] =<br>1100 mg/kg                    | [1] [2] |

Date of issue/Date of revision: 28/10/2022Date of previous issue: 10/02/2021Version: 22/18▶EKNODUR COMBI 3560-15 - All variantsLabel No : ♣0906

# **SECTION 3: Composition/information on ingredients**

|   |   |    | 9  |   |         |
|---|---|----|--|---|---------|
|   | EC: 215-535-7<br>CAS: 1330-20-7<br>Index: 601-022-00-9                                |    | Acute Tox. 4, H332<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>STOT SE 3, H335<br>STOT RE 2, H373<br>(oral, inhalation)<br>Asp. Tox. 1, H304 | ATE [Inhalation<br>(vapours)] = 11 mg/      |         |
| titanium dioxide  | REACH #:<br>01-2119489379-17<br>EC: 236-675-5<br>CAS: 13463-67-7                      | ≤3 | Carc. 2, H351<br>(inhalation)  | -   | [1] [*] |
| Ethylbenzene  | REACH #:<br>01-2119489370-35<br>EC: 202-849-4<br>CAS: 100-41-4<br>Index: 601-023-00-4 | ≤3 | Flam. Liq. 2, H225<br>Acute Tox. 4, H332<br>STOT RE 2, H373<br>(hearing organs) (oral,<br>inhalation)<br>Asp. Tox. 1, H304                       | ATE [Inhalation<br>(vapours)] = 11 mg/<br>I | [1] [2] |
| Reaction mass of Bis (1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate | REACH #:<br>01-2119491304-40  | ≤1 | Skin Sens. 1A, H317<br>Repr. 2, H361f<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1,<br>H410   | M [Acute] = 1<br>M [Chronic] = 1            | [1]     |
|   |   |    | See Section 16 for<br>the full text of the H<br>statements declared<br>above.  |   |         |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

#### Type

- Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

## **SECTION 4: First aid measures**

# 4.1 Description of first aid measures

**Eye contact** 

: Set medical attention immediately. Call a poison center or physician. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician.

Inhalation

: Set medical attention immediately. Call a poison center or physician. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

**Skin contact** 

Get medical attention immediately. Call a poison center or physician. Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 3/18 **Label No** : #0906

# **SECTION 4: First aid measures**

#### Ingestion

Eet medical attention immediately. Call a poison center or physician. Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Chemical burns must be treated promptly by a physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

#### **Protection of first-aiders**

: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

### 4.2 Most important symptoms and effects, both acute and delayed

### Over-exposure signs/symptoms

**Eye contact**: Adverse symptoms may include the following:

pain watering redness

Inhalation : No specific data.

**Skin contact**: Adverse symptoms may include the following:

pain or irritation redness

blistering may occur

**Ingestion** : Adverse symptoms may include the following:

stomach pains

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed.

The exposed person may need to be kept under medical surveillance for 48 hours.

**Specific treatments**: No specific treatment.

# **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

Suitable extinguishing

media

: Use dry chemical, CO2, water spray (fog) or foam.

Unsuitable extinguishing

media

: Do not use water jet.

#### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: Mammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

Label No : #0906

Hazardous combustion products

carbon dioxide carbon monoxide nitrogen oxides sulfur oxides metal oxide/oxides

### 5.3 Advice for firefighters

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 4/18

# SECTION 5: Firefighting measures

Special protective actions for fire-fighters

: Fromptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

**Special protective** equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

# SECTION 6: Accidental release measures

## 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Do not breathe vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders:

respecialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

## 6.2 Environmental precautions

Kvoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

## 6.3 Methods and material for containment and cleaning up

**Small spill** 

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

# Large spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

# 6.4 Reference to other sections

See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

# SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

# 7.1 Precautions for safe handling

**Protective measures** 

: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain

Date of issue/Date of revision : 28/10/2022 Date of previous issue · 10/02/2021 Version : 2

FÉKNODUR COMBI 3560-15 - All variants

5/18

**Label No** : **#**0906

# SECTION 7: Handling and storage

# Advice on general occupational hygiene

product residue and can be hazardous. Do not reuse container.

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

### **Seveso Directive - Reporting thresholds**

### **Danger criteria**

| Category    | Notification and MAPP threshold | Safety report threshold |  |
|-------------|---------------------------------|-------------------------|--|
| <b>P</b> 5c | 5000 tonne                      | 50000 tonne             |  |

#### 7.3 Specific end use(s)

: Not available. Recommendations : Not available. **Industrial sector specific** solutions

# SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

## Occupational exposure limits

| Product/ingredient name       | Exposure limit values   |
|-------------------------------|---|
| <mark>ଜ</mark> -Butyl acetate | EU OEL (Europe, 10/2019). Notes: list of indicative           |
|                               | occupational exposure limit values                            |
|                               | STEL: 150 ppm 15 minutes.                                     |
|                               | STEL: 723 mg/m³ 15 minutes.                                   |
|                               | TWA: 241 mg/m³ 8 hours.                                       |
|                               | TWA: 50 ppm 8 hours.  |
| Xylene                        | EU OEL (Europe, 10/2019). [xylene, mixed isomers] Absorbed    |
|                               | through skin. Notes: list of indicative occupational exposure |
|                               | limit values  |
|                               | TWA: 50 ppm 8 hours.  |
|                               | TWA: 221 mg/m³ 8 hours.                                       |
|                               | STEL: 100 ppm 15 minutes.                                     |
|                               | STEL: 442 mg/m³ 15 minutes.                                   |
| Ethylbenzene                  | EU OEL (Europe, 10/2019). Absorbed through skin. Notes: list  |
|                               | of indicative occupational exposure limit values              |
|                               | TWA: 100 ppm 8 hours.   |
|                               | TWA: 442 mg/m³ 8 hours.                                       |
|                               | STEL: 200 ppm 15 minutes.                                     |
|                               | STEL: 884 mg/m³ 15 minutes.                                   |

### **Recommended monitoring** procedures

If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace

Date of issue/Date of revision Date of previous issue : 10/02/2021 Version : 2 **Label No** : **#**0906

# **SECTION 8: Exposure controls/personal protection**

atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

## **DNELs/DMELs**

| Product/ingredient name   | Туре | Exposure                 | Value                  | Population            | Effects  |
|---|------|--------------------------|------------------------|-----------------------|----------|
| tetraethylN,N'-<br>(methylenedicyclohexane-4,1-diyl)<br>bis-dl-aspartate                                  | DNEL | Short term Oral          | 1.4 mg/kg<br>bw/day    | General<br>population | Systemic |
| and an appartate  | DNEL | Long term Oral           | 1.4 mg/kg<br>bw/day    | General population    | Systemic |
|   | DNEL | Short term Dermal        | 1.4 mg/kg<br>bw/day    | General population    | Systemic |
|   | DNEL | Long term Dermal         | 1.4 mg/kg<br>bw/day    | General population    | Systemic |
|   | DNEL | Long term Dermal         | 4 mg/kg<br>bw/day      | Workers               | Systemic |
|   | DNEL | Short term<br>Inhalation | 4.8 mg/m <sup>3</sup>  | General<br>population | Systemic |
|   | DNEL | Long term<br>Inhalation  | 4.8 mg/m³              | General population    | Systemic |
|   | DNEL | Long term Inhalation     | 28 mg/m³               | Workers               | Systemic |
|   | DNEL | Short term<br>Inhalation | 112 mg/m³              | Workers               | Systemic |
| 1,3,3-trimethyl-N-<br>(2-methylpropylidene)-5-[<br>(2-methylpropylidene)amino]-<br>cyclohexanemethylamine | DNEL | Long term Oral           | 0.526 mg/<br>kg bw/day | General<br>population | Systemic |
| cyclonexamemetrylarmine   | DNEL | Long term<br>Inhalation  | 150 mg/m³              | Workers               | Systemic |
| n-Butyl acetate   | DNEL | Long term Dermal         | 3.4 mg/kg<br>bw/day    | General<br>population | Systemic |
|   | DNEL | Long term Dermal         | 7 mg/kg<br>bw/day      | Workers               | Systemic |
|   | DNEL | Long term<br>Inhalation  | 12 mg/m³               | General<br>population | Systemic |
|   | DNEL | Long term<br>Inhalation  | 48 mg/m³               | Workers               | Systemic |
|   | DNEL | Short term Oral          | 2 mg/kg<br>bw/day      | General<br>population | Systemic |
|   | DNEL | Long term Oral           | 2 mg/kg<br>bw/day      | General population    | Systemic |
|   | DNEL | Short term Dermal        | 6 mg/kg<br>bw/day      | General population    | Systemic |
|   | DNEL | Short term Dermal        | 11 mg/kg<br>bw/day     | Workers               | Systemic |
|   | DNEL | Long term<br>Inhalation  | 35.7 mg/m³             | General population    | Local    |
|   | DNEL | Short term<br>Inhalation | 300 mg/m <sup>3</sup>  | General<br>population | Local    |
|   | DNEL | Short term<br>Inhalation | 300 mg/m <sup>3</sup>  | General population    | Systemic |
|   | DNEL | Long term<br>Inhalation  | 300 mg/m <sup>3</sup>  | Workers               | Local    |
|   | DNEL | Short term<br>Inhalation | 600 mg/m <sup>3</sup>  | Workers               | Local    |
|   | DNEL | Short term<br>Inhalation | 600 mg/m <sup>3</sup>  | Workers               | Systemic |
| bis(4-(1,2-bis(ethoxycarbonyl)<br>ethylamino)-3-methylcyclohexyl)<br>methane                              | DNEL | Short term Oral          | 4.2 mg/kg<br>bw/day    | General<br>population | Systemic |

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2

KNODUR COMBI 3560-15 - All variants

**Label No** : #0906

7/18

# SECTION 8: Exposure controls/personal protection

| ECTION 6. Exposure con                 | 11013/ | ersonal prote     | Clion                  |                         |               |
|--|--------|-------------------|------------------------|-------------------------|---------------|
|  | DNEL   | Long term Oral    | 4.2 mg/kg              | General                 | Systemic      |
|  |        |                   | bw/day                 | population              | ,             |
|  | DNEL   | Short term Dermal | 4.2 mg/kg              | General                 | Systemic      |
|  | DIVLL  | Onort tomi Bomia  | bw/day                 | population              | Cyclonno      |
|  | DNEL   | Long term Dermal  | 4.2 mg/kg              | General                 | Systemic      |
|  | DIVLL  | Long term berman  |                        |                         | Systemic      |
|  | DATE   |                   | bw/day                 | population              | 0             |
|  | DNEL   | Long term Dermal  | 11.9 mg/               | Workers                 | Systemic      |
|  |        |                   | kg bw/day              |                         |               |
|  | DNEL   | Short term        | 14.5 mg/m³             |                         | Systemic      |
|  |        | Inhalation        |                        | population              |               |
|  | DNEL   | Long term         | 14.5 mg/m <sup>3</sup> | General                 | Systemic      |
|  |        | Inhalation        |                        | population              |               |
|  | DNEL   | Long term         | 84 mg/m³               | Workers                 | Systemic      |
|  |        | Inhalation        | _                      |                         |               |
|  | DNEL   | Short term        | 672 mg/m <sup>3</sup>  | Workers                 | Systemic      |
|  |        | Inhalation        | J                      |                         | ,             |
| Xylene                                 | DNEL   | Long term Oral    | 1.6 mg/kg              | General                 | Systemic      |
| 74,5116                                | J.,    | Long torm oran    | bw/day                 | population              | Cycloniic     |
|  | DNEL   | Long term         | 14.8 mg/m <sup>3</sup> | General                 | Systemic      |
|  | DIVLL  | Inhalation        | 14.0 1119/111          | population              | Oysternic     |
|  | DNEL   | Long term         | 77 mg/m³               | Workers                 | Systemic      |
|  | DINEL  | Inhalation        | 77 mg/m                | Workers                 | Systemic      |
|  | DNIEL  |                   | 100//                  | Camaral                 | Customia      |
|  | DNEL   | Long term Dermal  | 108 mg/kg              | General                 | Systemic      |
|  | 5      |                   | bw/day                 | population              |               |
|  | DNEL   | Long term Dermal  | 180 mg/kg              | Workers                 | Systemic      |
|  |        |                   | bw/day                 |                         |               |
|  | DNEL   | Short term        | 289 mg/m <sup>3</sup>  | Workers                 | Local         |
|  |        | Inhalation        |                        |                         |               |
|  | DNEL   | Short term        | 289 mg/m <sup>3</sup>  | Workers                 | Systemic      |
|  |        | Inhalation        |                        |                         |               |
|  | DNEL   | Long term         | 65.3 mg/m <sup>3</sup> | General                 | Local         |
|  |        | Inhalation        | Ū                      | population              |               |
|  | DNEL   | Short term        | 260 mg/m <sup>3</sup>  | General                 | Local         |
|  |        | Inhalation        |                        | population              |               |
|  | DNEL   | Short term        | 260 mg/m <sup>3</sup>  | General                 | Systemic      |
|  | J.,    | Inhalation        | 200 mg/m               | population              | Cyclenno      |
|  | DNEL   | Long term         | 221 mg/m <sup>3</sup>  | Workers                 | Local         |
|  | DIVLE  | Inhalation        | 22 i ilig/ili          | VVOINCIS                | Local         |
| titanium dioxide                       | DNEL   | Long term         | 10 mg/m³               | Workers                 | Local         |
| III. III. III. III. III. III. III. III | PINEL  |                   | 10 mg/m                | MOIVEIS                 | LUCAI         |
|  | חאבו   | Inhalation        | 700 m = //. =          | Conorol                 | Customic      |
|  | DNEL   | Long term Oral    | 700 mg/kg              | General                 | Systemic      |
| Cthydb arman -                         | ראבי   | Lammater Coll     | bw/day                 | population              | Curata waii a |
| Ethylbenzene                           | DNEL   | Long term Oral    | 1.6 mg/kg              | General                 | Systemic      |
|  |        |                   | bw/day                 | population              | .             |
|  | DNEL   | Long term         | 15 mg/m³               | General                 | Systemic      |
|  |        | Inhalation        |                        | population              |               |
|  | DNEL   | Long term         | 77 mg/m³               | Workers                 | Systemic      |
|  |        | Inhalation        |                        |                         |               |
|  | DNEL   | Long term Dermal  | 180 mg/kg              | Workers                 | Systemic      |
|  |        |                   | bw/day                 |                         |               |
|  | DNEL   | Short term        | 293 mg/m <sup>3</sup>  | Workers                 | Local         |
|  |        | Inhalation        |                        |                         |               |
|  | DMEL   | Long term         | 442 mg/m <sup>3</sup>  | Workers                 | Local         |
|  |        | Inhalation        |                        | · · · · · · · · · · · · |               |
|  | DMEL   | Short term        | 884 mg/m³              | Workers                 | Systemic      |
|  | DIVILL | Inhalation        | Jo- mg/m               | TTOINGIG                | Systemio      |
|  |        | minalation        |                        |                         |               |

# **PNECs**

No PNECs available

# 8.2 Exposure controls

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 8/18 **Label No** : **#**0906

# **SECTION 8: Exposure controls/personal protection**

# Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

#### **Individual protection measures**

### **Hygiene measures**

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

## **Eye/face protection**

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles and/or face shield. If inhalation hazards exist, a full-face respirator may be required instead.

# Skin protection Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Recommendations: Wear suitable gloves tested to EN374.

< 1 hour (breakthrough time): Mitrile gloves. thickness > 0.3 mm

1 - 4 hours (breakthrough time): polyvinyl alcohol (PVA) thickness > 0.3 mm or 4H / Silver Shield® gloves.

# **Body protection**

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.

### Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

#### **Respiratory protection**

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type:

Filter type (spray application):

# **Environmental exposure** controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 9/18

FEKNODUR COMBI 3560-15 - All variants

**Label No** : #0906

# **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

# 9.1 Information on basic physical and chemical properties

**Appearance** 

: Liquid. **Physical state** : Various Colour : Slight **Odour** 

: Not available. **Odour threshold** : Not available. Melting point/freezing point

Initial boiling point and

boiling range

| Ingredient name | °C    | °F    | Method   |
|-----------------|-------|-------|----------|
| pzButyl acetate | 126   | 258.8 | OECD 103 |
| Ethylbenzene    | 136.1 | 277   | OECD 104 |

**Flammability** : Not available. Lower and upper explosion : Lower: 0.8% Upper: 7.6%

: Closed cup: 25°C (77°F) Flash point

**Auto-ignition temperature** 

| Ingredient name  | °C  | °F  | Method  |
|--|-----|-----|---------|
| traethylN,N'-(methylenedicyclohexane-4,1-diyl)bis-dl-aspartate | 375 | 707 | EU A.15 |
| n-Butyl acetate  | 415 | 779 | EU A.15 |

: Not available. **Decomposition temperature** pН : Not applicable. : Not available. **Viscosity** 

Solubility(ies)

Not available.

: Not available. Solubility in water Partition coefficient: n-octanol/ : Not applicable.

water

Vapour pressure

|                               | Vapour Pressure at 20°C |     |                | Va    | pour pressu | re at 50°C |
|-------------------------------|-------------------------|-----|----------------|-------|-------------|------------|
| Ingredient name               | mm Hg                   | kPa | Method         | mm Hg | kPa         | Method     |
| <mark>p-</mark> Butyl acetate | 11.25                   | 1.5 | DIN EN 13016-2 |       |             |            |
| Ethylbenzene                  | 9.3                     | 1.2 |                |       |             |            |

**Relative density** : Not available. : 1.6 g/cm<sup>3</sup> **Density** : Not available. Vapour density : Not available. **Explosive properties** : Not available. **Oxidising properties** 

**Particle characteristics** 

: Not applicable. Median particle size

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 10/18 Label No : #0906

# **SECTION 10: Stability and reactivity**

10.1 Reactivity

: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability

: The product is stable.

10.3 Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid

: Kvoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.

10.5 Incompatible materials

: Reactive or incompatible with the following materials:

oxidising materials

10.6 Hazardous decomposition products

: Inder normal conditions of storage and use, hazardous decomposition products should not be produced.

# **SECTION 11: Toxicological information**

## 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

# **Acute toxicity**

| Product/ingredient name       | Result                    | Species | Dose        | Exposure |
|-------------------------------|---------------------------|---------|-------------|----------|
| <mark>ଜ-</mark> Butyl acetate | LC50 Inhalation Vapour    | Rat     | 0.74 mg/l   | 4 hours  |
|                               | LD50 Dermal               | Rabbit  | 14112 mg/kg | -        |
|                               | LD50 Oral                 | Rat     | 10760 mg/kg | -        |
| Xylene                        | LC50 Inhalation Vapour    | Rat     | 21.7 mg/l   | 4 hours  |
|                               | LD50 Oral                 | Rat     | 4300 mg/kg  | -        |
| Ethylbenzene                  | LC50 Inhalation Dusts and | Rat     | 29000 mg/l  | 4 hours  |
|                               | mists                     |         |             |          |
|                               | LD50 Dermal               | Rabbit  | 15400 mg/kg | -        |
|                               | LD50 Oral                 | Rat     | 3500 mg/kg  | -        |
| Reaction mass of Bis          | LD50 Dermal               | Rat     | >3170 mg/kg | -        |
| (1,2,2,6,6-pentamethyl-       |                           |         |             |          |
| 4-piperidyl) sebacate and     |                           |         |             |          |
| Methyl                        |                           |         |             |          |
| 1,2,2,6,6-pentamethyl-        |                           |         |             |          |
| 4-piperidyl sebacate          |                           |         |             |          |
|                               | LD50 Oral                 | Rat     | 3230 mg/kg  | -        |

### Conclusion/Summary

: Based on available data, the classification criteria are not met.

### **Acute toxicity estimates**

| Route                         | ATE value      |  |
|-------------------------------|----------------|--|
| <b>D</b> ermal <b>D</b> ermal | 23349.51 mg/kg |  |
| Inhalation (vapours)          | 191.47 mg/l    |  |

### **Irritation/Corrosion**

Date of issue/Date of revision

| Product/ingredient name                    | Result                   | Species | Score | Exposure      | Observation |
|--|--------------------------|---------|-------|---------------|-------------|
| <mark>ଜ</mark> -Butyl acetate              | Eyes - Moderate irritant | Rabbit  | -     | 100 mg        | -           |
| -  | Skin - Moderate irritant | Rabbit  | -     | 24 hours 500  | -           |
|  |                          |         |       | mg            |             |
| bis(4-(1,2-bis (ethoxycarbonyl)ethylamino) | Eyes - Mild irritant     | Rabbit  | -     | -             | -           |
| -3-methylcyclohexyl)methane                |                          |         |       |               |             |
| Xylene                                     | Eyes - Mild irritant     | Rabbit  | -     | 87 mg         | -           |
|  | Eyes - Severe irritant   | Rabbit  | -     | 24 hours 5    | -           |
|  |                          |         |       | mg            |             |
|  | Skin - Mild irritant     | Rat     | -     | 8 hours 60 uL | -           |
|  | Skin - Moderate irritant | Rabbit  | -     | 100 %         | -           |
|  | Skin - Moderate irritant | Rabbit  | -     | 24 hours 500  | -           |
|  |                          |         |       | mg            |             |
|  |                          |         |       |               |             |

Date of previous issue

FEKNODUR COMBI 3560-15 - All variants

: 28/10/2022

: 10/02/2021 **Version** : 2

**Label No** : 40906

11/18

# **SECTION 11: Toxicological information**

| titanium dioxide | Skin - Mild irritant   | Human  | - | 72 hours 300 | - |
|------------------|------------------------|--------|---|--------------|---|
|                  |                        |        |   | ug l         |   |
| Ethylbenzene     | Eyes - Severe irritant | Rabbit | - | 500 mg       | - |
|                  | Skin - Mild irritant   | Rabbit | - | 24 hours 15  | - |
|                  |                        |        |   | mg           |   |

**Conclusion/Summary** 

: Causes severe skin burns and eye damage.

**Sensitisation** 

**Conclusion/Summary** : May cause an allergic skin reaction.

**Mutagenicity** 

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

**Carcinogenicity** 

⊮has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

: Based on available data, the classification criteria are not met. **Conclusion/Summary** 

Reproductive toxicity

: Based on available data, the classification criteria are not met. **Conclusion/Summary** 

**Teratogenicity** 

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

| Product/ingredient name | Category                 | Route of exposure | Target organs                                       |
|-------------------------|--------------------------|-------------------|---|
| P-Butyl acetate Xylene  | Category 3<br>Category 3 | -                 | Narcotic effects<br>Respiratory tract<br>irritation |

## Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category   | Route of exposure                 | Target organs  |
|-------------------------|------------|-----------------------------------|----------------|
| Xylene                  | Category 2 | oral, inhalation oral, inhalation | -              |
| Ethylbenzene            | Category 2 |                                   | hearing organs |

#### **Aspiration hazard**

| Product/ingredient name | Result                         |
|-------------------------|--------------------------------|
| Kylene                  | ASPIRATION HAZARD - Category 1 |
| Ethylbenzene            | ASPIRATION HAZARD - Category 1 |

**Information on likely routes**: Not available.

of exposure

Potential acute health effects

**Eye contact** : Causes serious eye damage.

: No known significant effects or critical hazards. Inhalation

: Causes severe burns. May cause an allergic skin reaction. **Skin contact** 

: No known significant effects or critical hazards. Ingestion

## Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : Adverse symptoms may include the following:

> pain watering redness

Inhalation : No specific data.

: Adverse symptoms may include the following: Skin contact

pain or irritation

redness

blistering may occur

Date of issue/Date of revision : 28/10/2022 Date of previous issue · 10/02/2021 Version : 2 12/18 Label No : #0906

# **SECTION 11: Toxicological information**

: Adverse symptoms may include the following: Ingestion

stomach pains

## Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

**Potential immediate** 

: Not available.

effects

: Not available. Potential delayed effects

**Long term exposure** 

**Potential immediate** 

: Not available.

effects

: Not available. Potential delayed effects

Potential chronic health effects

Not available.

**Conclusion/Summary** : Not available.

: Once sensitized, a severe allergic reaction may occur when subsequently exposed **General** 

to very low levels.

: No known significant effects or critical hazards. Carcinogenicity Mutagenicity : No known significant effects or critical hazards. : No known significant effects or critical hazards. Reproductive toxicity

#### 11.2 Information on other hazards

## 11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

# **SECTION 12: Ecological information**

# 12.1 Toxicity

| Product/ingredient name   | Result                                     | Species                                       | Exposure            |
|---|--|---|---------------------|
| etraethylN,N'-<br>(methylenedicyclohexane-<br>4,1-diyl)bis-dl-aspartate   | Acute EC50 113 mg/l                        | Algae   | 72 hours            |
| i, i diyi)zie di departate  | Acute EC50 88.6 mg/l                       | Daphnia                                       | 48 hours            |
|   | Acute LC50 66 mg/l                         | Fish  | 96 hours            |
| n-Butyl acetate   | Acute LC50 32 mg/l Marine water            | Crustaceans - Artemia salina                  | 48 hours            |
|   | Acute LC50 18000 µg/l Fresh water          | Fish - Pimephales promelas                    | 96 hours            |
| bis(4-(1,2-bis  | Acute EC50 113 mg/l                        | Algae   | 72 hours            |
| (ethoxycarbonyl)ethylamino)   | _  |   |                     |
| -3-methylcyclohexyl)methane   |  |   |                     |
|   | Acute EC50 88.6 mg/l                       | Daphnia                                       | 48 hours            |
|   | Acute LC50 66 mg/l                         | Fish  | 96 hours            |
| titanium dioxide  | Acute LC50 3 mg/l Fresh water              | Crustaceans - Ceriodaphnia dubia - Neonate    | 48 hours            |
|   | Acute LC50 6.5 mg/l Fresh water            | Daphnia - Daphnia pulex -<br>Neonate          | 48 hours            |
|   | Acute LC50 >1000000 μg/l Marine water      | Fish - Fundulus heteroclitus                  | 96 hours            |
| Reaction mass of Bis (1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate | EC50 1.68 mg/l                             | Aquatic plants -<br>Desmodesmodus subspicatus | 72 hours            |
| i piporiaji oobaoato  | Acute LC50 0.9 mg/l<br>Chronic NOEC 1 mg/l | Fish - Brachydanio rerio<br>Daphnia           | 96 hours<br>21 days |

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 13/18 Label No : #0906

# **SECTION 12: Ecological information**

**Conclusion/Summary**: Farmful to aquatic life with long lasting effects.

## 12.2 Persistence and degradability

**Conclusion/Summary**: This product has not been tested for biodegradation.

### 12.3 Bioaccumulative potential

| Product/ingredient name     | LogPow | BCF         | Potential |
|-----------------------------|--------|-------------|-----------|
| tetraethylN,N'-             | 5.16   | 0.25        | low       |
| (methylenedicyclohexane-    |        |             |           |
| 4,1-diyl)bis-dl-aspartate   |        |             |           |
| n-Butyl acetate             | 2.3    | -           | low       |
| bis(4-(1,2-bis              | 5.99   | 0.25        | low       |
| (ethoxycarbonyl)ethylamino) |        |             |           |
| -3-methylcyclohexyl)methane |        |             |           |
| Xylene                      | 3.12   | 8.1 to 25.9 | low       |
| Ethylbenzene                | 3.6    | -           | low       |

#### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

#### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

# SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** 

European waste catalogue (EWC)

: The classification of the product may meet the criteria for a hazardous waste.

**: 0**80111\*, 200127\*

**Packaging** 

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** 

: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Label No : #0906

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 14/18

# **SECTION 14: Transport information**

|                                    | ADR/RID  | ADN  | IMDG   | IATA   |
|------------------------------------|--|--|--|--|
| 14.1 UN number or ID number        | <b>☑</b> N2924   | <b>☑</b> N2924   | <b>☑</b> N2924   | <b>№</b> N2924   |
| 14.2 UN proper shipping name       | ELAMMABLE LIQUID, CORROSIVE, N.O.S. (xylene, 1,3,3-trimethyl-N-(2-methylpropylidene) -5-[ (2-methylpropylidene) amino] cyclohexanemethylamine) | ELAMMABLE LIQUID, CORROSIVE, N.O.S. (xylene, 1,3,3-trimethyl-N-(2-methylpropylidene) -5-[ (2-methylpropylidene) amino] cyclohexanemethylamine) | ELAMMABLE LIQUID, CORROSIVE, N.O.S. (xylene, 1,3,3-trimethyl-N-(2-methylpropylidene) -5-[ (2-methylpropylidene) amino] cyclohexanemethylamine) | ELAMMABLE LIQUID, CORROSIVE, N.O.S. (xylene, 1,3,3-trimethyl-N-(2-methylpropylidene) -5-[ (2-methylpropylidene) amino] cyclohexanemethylamine) |
| 14.3 Transport<br>hazard class(es) | <b>3</b> (8)   | <b>3</b> (8)   | <b>3</b> (8)   | <b>3</b> (8)   |
| 14.4 Packing group                 | IM.  | ĮV.  | IM.  | ĮV.  |
| 14.5<br>Environmental<br>hazards   | <b>№</b> o.  | No.  | <b>№</b> o.  | No.  |

**Additional information** 

ADR/RID : Tunnel code (D/E)

14.6 Special precautions for

user

: Fransport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO

instruments

: Not relevant/applicable due to nature of the product.

# **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Other EU regulations

**Industrial emissions** (integrated pollution prevention and control) - : Not listed

**Air** 

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 15/18 Label No : #0906

# **SECTION 15: Regulatory information**

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Water

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

**Persistent Organic Pollutants** 

Not listed.

**Seveso Directive** 

This product is controlled under the Seveso Directive.

**Danger criteria** 

Category

P<sub>5</sub>c

**National regulations** 

**International regulations** 

**Chemical Weapon Convention List Schedules I, II & III Chemicals** 

Not listed.

**Montreal Protocol** 

Not listed.

**Stockholm Convention on Persistent Organic Pollutants** 

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

**UNECE Aarhus Protocol on POPs and Heavy Metals** 

Not listed.

15.2 Chemical safety

assessment

: This product contains substances for which Chemical Safety Assessments are still

Label No : #0906

required.

# **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and

: ATE = Acute Toxicity Estimate

acronyms CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/20081

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 16/18

# **SECTION 16: Other information**

| Classification            | Justification         |
|---------------------------|-----------------------|
| <b>F</b> am. Liq. 3, H226 | On basis of test data |
| Skin Corr. 1C, H314       | Calculation method    |
| Eye Dam. 1, H318          | Calculation method    |
| Skin Sens. 1, H317        | Calculation method    |
| Aquatic Chronic 3, H412   | Calculation method    |

## Full text of abbreviated H statements

| <b>⊮</b> 225 | Highly flammable liquid and vapour.                                |
|--------------|--|
| H226         | Flammable liquid and vapour.                                       |
| H304         | May be fatal if swallowed and enters airways.                      |
| H312         | Harmful in contact with skin.                                      |
| H314         | Causes severe skin burns and eye damage.                           |
| H315         | Causes skin irritation.  |
| H317         | May cause an allergic skin reaction.                               |
| H318         | Causes serious eye damage.   |
| H319         | Causes serious eye irritation.                                     |
| H332         | Harmful if inhaled.  |
| H335         | May cause respiratory irritation.                                  |
| H336         | May cause drowsiness or dizziness.                                 |
| H351         | Suspected of causing cancer.                                       |
| H361f        | Suspected of damaging fertility.                                   |
| H373         | May cause damage to organs through prolonged or repeated exposure. |
| H400         | Very toxic to aquatic life.  |
| H410         | Very toxic to aquatic life with long lasting effects.              |
| H412         | Harmful to aquatic life with long lasting effects.                 |
| EUH066       | Repeated exposure may cause skin dryness or cracking.              |

## Full text of classifications [CLP/GHS]

| Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 Aquatic Chronic 3 Asp. Tox. 1              | ACUTE TOXICITY - Category 4 SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 ASPIRATION HAZARD - Category 1   |
|---|---|
| Carc. 2 Eye Dam. 1 Eye Irrit. 2 Flam. Liq. 2 Flam. Liq. 3 Repr. 2                         | CARCINOGENICITY - Category 2 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 FLAMMABLE LIQUIDS - Category 2 FLAMMABLE LIQUIDS - Category 3 REPRODUCTIVE TOXICITY - Category 2   |
| Skin Corr. 1C<br>Skin Irrit. 2<br>Skin Sens. 1<br>Skin Sens. 1A<br>STOT RE 2<br>STOT SE 3 | SKIN CORROSION/IRRITATION - Čategory 1C SKIN CORROSION/IRRITATION - Category 2 SKIN SENSITISATION - Category 1 SKIN SENSITISATION - Category 1A SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3 |

Date of issue/ Date of : 28/10/2022

revision

Date of previous issue : 10/02/2021

Version : 2

KNODUR COMBI 3560-15

### **M** variants

## **Notice to reader**

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision : 28/10/2022 Date of previous issue : 10/02/2021 Version : 2 17/18

FEKNODUR COMBI 3560-15 - All variants

**Label No** : **4**0906

Date of issue/Date of revision Version : 2 : 28/10/2022 Date of previous issue : 10/02/2021 18/18